Table of Content

1 Anti-Nuclear Radiation Drug Market Overview
1.1 Product Overview and Scope of Anti-Nuclear Radiation Drug
1.2 Anti-Nuclear Radiation Drug Segment by Type
1.2.1 Global Anti-Nuclear Radiation Drug Market Value Comparison by Type (2024-2034)
1.2.2 Potassium Iodide (KI)
1.2.3 Prussian Blue
1.2.4 Diethylenetriamine Pentaacetate (DTPA)
1.2.5 Filgrastim
1.2.6 Amifostine
1.2.7 Ex-Rad
1.3 Anti-Nuclear Radiation Drug Segment by Sales Channel
1.3.1 Global Anti-Nuclear Radiation Drug Market Value by Sales Channel: (2024-2034)
1.3.2 Online Sales
1.3.3 Offline Sales
1.4 Global Anti-Nuclear Radiation Drug Market Size Estimates and Forecasts
1.4.1 Global Anti-Nuclear Radiation Drug Revenue 2018-2029
1.4.2 Global Anti-Nuclear Radiation Drug Sales 2018-2029
1.4.3 Global Anti-Nuclear Radiation Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-Nuclear Radiation Drug Market Competition by Manufacturers
2.1 Global Anti-Nuclear Radiation Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Anti-Nuclear Radiation Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Anti-Nuclear Radiation Drug Average Price by Manufacturers (2018-2024)
2.4 Global Anti-Nuclear Radiation Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Product Type & Application
2.7 Anti-Nuclear Radiation Drug Market Competitive Situation and Trends
2.7.1 Anti-Nuclear Radiation Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Nuclear Radiation Drug Players Market Share by Revenue
2.7.3 Global Anti-Nuclear Radiation Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Nuclear Radiation Drug Retrospective Market Scenario by Region
3.1 Global Anti-Nuclear Radiation Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-Nuclear Radiation Drug Global Anti-Nuclear Radiation Drug Sales by Region: 2018-2029
3.2.1 Global Anti-Nuclear Radiation Drug Sales by Region: 2018-2024
3.2.2 Global Anti-Nuclear Radiation Drug Sales by Region: 2024-2029
3.3 Global Anti-Nuclear Radiation Drug Global Anti-Nuclear Radiation Drug Revenue by Region: 2018-2029
3.3.1 Global Anti-Nuclear Radiation Drug Revenue by Region: 2018-2024
3.3.2 Global Anti-Nuclear Radiation Drug Revenue by Region: 2024-2029
3.4 North America Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.4.1 North America Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.4.3 North America Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.5.1 Europe Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.5.3 Europe Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.7.1 Latin America Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.7.3 Latin America Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-Nuclear Radiation Drug Sales by Type (2018-2029)
4.1.1 Global Anti-Nuclear Radiation Drug Sales by Type (2018-2024)
4.1.2 Global Anti-Nuclear Radiation Drug Sales by Type (2024-2029)
4.1.3 Global Anti-Nuclear Radiation Drug Sales Market Share by Type (2018-2029)
4.2 Global Anti-Nuclear Radiation Drug Revenue by Type (2018-2029)
4.2.1 Global Anti-Nuclear Radiation Drug Revenue by Type (2018-2024)
4.2.2 Global Anti-Nuclear Radiation Drug Revenue by Type (2024-2029)
4.2.3 Global Anti-Nuclear Radiation Drug Revenue Market Share by Type (2018-2029)
4.3 Global Anti-Nuclear Radiation Drug Price by Type (2018-2029)
5 Segment by Sales Channel
5.1 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029)
5.1.1 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2024)
5.1.2 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2024-2029)
5.1.3 Global Anti-Nuclear Radiation Drug Sales Market Share by Sales Channel (2018-2029)
5.2 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2018-2029)
5.2.1 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2018-2024)
5.2.2 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2024-2029)
5.2.3 Global Anti-Nuclear Radiation Drug Revenue Market Share by Sales Channel (2018-2029)
5.3 Global Anti-Nuclear Radiation Drug Price by Sales Channel (2018-2029)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Amgen Anti-Nuclear Radiation Drug Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Humanwell Healthcare
6.2.1 Humanwell Healthcare Corporation Information
6.2.2 Humanwell Healthcare Description and Business Overview
6.2.3 Humanwell Healthcare Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Humanwell Healthcare Anti-Nuclear Radiation Drug Product Portfolio
6.2.5 Humanwell Healthcare Recent Developments/Updates
6.3 Jiangsu Wuzhong Pharmaceutical Group
6.3.1 Jiangsu Wuzhong Pharmaceutical Group Corporation Information
6.3.2 Jiangsu Wuzhong Pharmaceutical Group Description and Business Overview
6.3.3 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Product Portfolio
6.3.5 Jiangsu Wuzhong Pharmaceutical Group Recent Developments/Updates
6.4 Hisun Pharmaceutical
6.4.1 Hisun Pharmaceutical Corporation Information
6.4.2 Hisun Pharmaceutical Description and Business Overview
6.4.3 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.4.5 Hisun Pharmaceutical Recent Developments/Updates
6.5 Beijing Centergate Technologies
6.5.1 Beijing Centergate Technologies Corporation Information
6.5.2 Beijing Centergate Technologies Description and Business Overview
6.5.3 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Product Portfolio
6.5.5 Beijing Centergate Technologies Recent Developments/Updates
6.6 Lisheng Pharmaceutical
6.6.1 Lisheng Pharmaceutical Corporation Information
6.6.2 Lisheng Pharmaceutical Description and Business Overview
6.6.3 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.6.5 Lisheng Pharmaceutical Recent Developments/Updates
6.7 Bayer AG
6.6.1 Bayer AG Corporation Information
6.6.2 Bayer AG Description and Business Overview
6.6.3 Bayer AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Bayer AG Anti-Nuclear Radiation Drug Product Portfolio
6.7.5 Bayer AG Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 GlaxoSmithKline Anti-Nuclear Radiation Drug Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Pfizer Anti-Nuclear Radiation Drug Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Onconova
6.10.1 Onconova Corporation Information
6.10.2 Onconova Description and Business Overview
6.10.3 Onconova Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Onconova Anti-Nuclear Radiation Drug Product Portfolio
6.10.5 Onconova Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG Anti-Nuclear Radiation Drug Description and Business Overview
6.11.3 Novartis AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Novartis AG Anti-Nuclear Radiation Drug Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Teva Pharmaceuticals
6.12.1 Teva Pharmaceuticals Corporation Information
6.12.2 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Description and Business Overview
6.12.3 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Product Portfolio
6.12.5 Teva Pharmaceuticals Recent Developments/Updates
6.13 Clinigen
6.13.1 Clinigen Corporation Information
6.13.2 Clinigen Anti-Nuclear Radiation Drug Description and Business Overview
6.13.3 Clinigen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Clinigen Anti-Nuclear Radiation Drug Product Portfolio
6.13.5 Clinigen Recent Developments/Updates
6.14 Sun Pharmaceutical
6.14.1 Sun Pharmaceutical Corporation Information
6.14.2 Sun Pharmaceutical Anti-Nuclear Radiation Drug Description and Business Overview
6.14.3 Sun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Sun Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.14.5 Sun Pharmaceutical Recent Developments/Updates
6.15 Taj Pharmaceuticals
6.15.1 Taj Pharmaceuticals Corporation Information
6.15.2 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Description and Business Overview
6.15.3 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Product Portfolio
6.15.5 Taj Pharmaceuticals Recent Developments/Updates
6.16 Merro Pharmaceutical
6.16.1 Merro Pharmaceutical Corporation Information
6.16.2 Merro Pharmaceutical Anti-Nuclear Radiation Drug Description and Business Overview
6.16.3 Merro Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Merro Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.16.5 Merro Pharmaceutical Recent Developments/Updates
6.17 Luye Pharma
6.17.1 Luye Pharma Corporation Information
6.17.2 Luye Pharma Anti-Nuclear Radiation Drug Description and Business Overview
6.17.3 Luye Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Luye Pharma Anti-Nuclear Radiation Drug Product Portfolio
6.17.5 Luye Pharma Recent Developments/Updates
6.18 Mingren Pharma
6.18.1 Mingren Pharma Corporation Information
6.18.2 Mingren Pharma Anti-Nuclear Radiation Drug Description and Business Overview
6.18.3 Mingren Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Mingren Pharma Anti-Nuclear Radiation Drug Product Portfolio
6.18.5 Mingren Pharma Recent Developments/Updates
6.19 Gilead Sciences
6.19.1 Gilead Sciences Corporation Information
6.19.2 Gilead Sciences Anti-Nuclear Radiation Drug Description and Business Overview
6.19.3 Gilead Sciences Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Gilead Sciences Anti-Nuclear Radiation Drug Product Portfolio
6.19.5 Gilead Sciences Recent Developments/Updates
6.20 Johnson & Johnson
6.20.1 Johnson & Johnson Corporation Information
6.20.2 Johnson & Johnson Anti-Nuclear Radiation Drug Description and Business Overview
6.20.3 Johnson & Johnson Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.20.4 Johnson & Johnson Anti-Nuclear Radiation Drug Product Portfolio
6.20.5 Johnson & Johnson Recent Developments/Updates
6.21 Merck KGaA
6.21.1 Merck KGaA Corporation Information
6.21.2 Merck KGaA Anti-Nuclear Radiation Drug Description and Business Overview
6.21.3 Merck KGaA Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.21.4 Merck KGaA Anti-Nuclear Radiation Drug Product Portfolio
6.21.5 Merck KGaA Recent Developments/Updates
6.22 Genentech Inc.
6.22.1 Genentech Inc. Corporation Information
6.22.2 Genentech Inc. Anti-Nuclear Radiation Drug Description and Business Overview
6.22.3 Genentech Inc. Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
6.22.4 Genentech Inc. Anti-Nuclear Radiation Drug Product Portfolio
6.22.5 Genentech Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Nuclear Radiation Drug Industry Chain Analysis
7.2 Anti-Nuclear Radiation Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Nuclear Radiation Drug Production Mode & Process
7.4 Anti-Nuclear Radiation Drug Sales and Marketing
7.4.1 Anti-Nuclear Radiation Drug Sales Channels
7.4.2 Anti-Nuclear Radiation Drug Distributors
7.5 Anti-Nuclear Radiation Drug Customers
8 Anti-Nuclear Radiation Drug Market Dynamics
8.1 Anti-Nuclear Radiation Drug Industry Trends
8.2 Anti-Nuclear Radiation Drug Market Drivers
8.3 Anti-Nuclear Radiation Drug Market Challenges
8.4 Anti-Nuclear Radiation Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Nuclear Radiation Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Anti-Nuclear Radiation Drug Market Value Comparison by Sales Channel (2024-2034) & (US$ Million)
Table 3. Global Anti-Nuclear Radiation Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Anti-Nuclear Radiation Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Anti-Nuclear Radiation Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Anti-Nuclear Radiation Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Anti-Nuclear Radiation Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Anti-Nuclear Radiation Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Anti-Nuclear Radiation Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Product Type & Application
Table 12. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-Nuclear Radiation Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Nuclear Radiation Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-Nuclear Radiation Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Anti-Nuclear Radiation Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Anti-Nuclear Radiation Drug Sales Market Share by Region (2018-2024)
Table 19. Global Anti-Nuclear Radiation Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Anti-Nuclear Radiation Drug Sales Market Share by Region (2024-2029)
Table 21. Global Anti-Nuclear Radiation Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Anti-Nuclear Radiation Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Anti-Nuclear Radiation Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Anti-Nuclear Radiation Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Anti-Nuclear Radiation Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Anti-Nuclear Radiation Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Anti-Nuclear Radiation Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Anti-Nuclear Radiation Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Anti-Nuclear Radiation Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Anti-Nuclear Radiation Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Anti-Nuclear Radiation Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Anti-Nuclear Radiation Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Anti-Nuclear Radiation Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Anti-Nuclear Radiation Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Anti-Nuclear Radiation Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Anti-Nuclear Radiation Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Anti-Nuclear Radiation Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Anti-Nuclear Radiation Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Anti-Nuclear Radiation Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Anti-Nuclear Radiation Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Anti-Nuclear Radiation Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Anti-Nuclear Radiation Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Anti-Nuclear Radiation Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Anti-Nuclear Radiation Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Anti-Nuclear Radiation Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Anti-Nuclear Radiation Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Anti-Nuclear Radiation Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Anti-Nuclear Radiation Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-Nuclear Radiation Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Anti-Nuclear Radiation Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Anti-Nuclear Radiation Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Anti-Nuclear Radiation Drug Sales Market Share by Type (2018-2024)
Table 53. Global Anti-Nuclear Radiation Drug Sales Market Share by Type (2024-2029)
Table 54. Global Anti-Nuclear Radiation Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Anti-Nuclear Radiation Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Anti-Nuclear Radiation Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Anti-Nuclear Radiation Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Anti-Nuclear Radiation Drug Sales (K Units) by Sales Channel (2018-2024)
Table 61. Global Anti-Nuclear Radiation Drug Sales (K Units) by Sales Channel (2024-2029)
Table 62. Global Anti-Nuclear Radiation Drug Sales Market Share by Sales Channel (2018-2024)
Table 63. Global Anti-Nuclear Radiation Drug Sales Market Share by Sales Channel (2024-2029)
Table 64. Global Anti-Nuclear Radiation Drug Revenue (US$ Million) by Sales Channel (2018-2024)
Table 65. Global Anti-Nuclear Radiation Drug Revenue (US$ Million) by Sales Channel (2024-2029)
Table 66. Global Anti-Nuclear Radiation Drug Revenue Market Share by Sales Channel (2018-2024)
Table 67. Global Anti-Nuclear Radiation Drug Revenue Market Share by Sales Channel (2024-2029)
Table 68. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Sales Channel (2018-2024)
Table 69. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Sales Channel (2024-2029)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Amgen Anti-Nuclear Radiation Drug Product
Table 74. Amgen Recent Developments/Updates
Table 75. Humanwell Healthcare Corporation Information
Table 76. Humanwell Healthcare Description and Business Overview
Table 77. Humanwell Healthcare Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Humanwell Healthcare Anti-Nuclear Radiation Drug Product
Table 79. Humanwell Healthcare Recent Developments/Updates
Table 80. Jiangsu Wuzhong Pharmaceutical Group Corporation Information
Table 81. Jiangsu Wuzhong Pharmaceutical Group Description and Business Overview
Table 82. Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Product
Table 84. Jiangsu Wuzhong Pharmaceutical Group Recent Developments/Updates
Table 85. Hisun Pharmaceutical Corporation Information
Table 86. Hisun Pharmaceutical Description and Business Overview
Table 87. Hisun Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Hisun Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 89. Hisun Pharmaceutical Recent Developments/Updates
Table 90. Beijing Centergate Technologies Corporation Information
Table 91. Beijing Centergate Technologies Description and Business Overview
Table 92. Beijing Centergate Technologies Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Beijing Centergate Technologies Anti-Nuclear Radiation Drug Product
Table 94. Beijing Centergate Technologies Recent Developments/Updates
Table 95. Lisheng Pharmaceutical Corporation Information
Table 96. Lisheng Pharmaceutical Description and Business Overview
Table 97. Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 99. Lisheng Pharmaceutical Recent Developments/Updates
Table 100. Bayer AG Corporation Information
Table 101. Bayer AG Description and Business Overview
Table 102. Bayer AG Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Bayer AG Anti-Nuclear Radiation Drug Product
Table 104. Bayer AG Recent Developments/Updates
Table 105. GlaxoSmithKline Corporation Information
Table 106. GlaxoSmithKline Description and Business Overview
Table 107. GlaxoSmithKline Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. GlaxoSmithKline Anti-Nuclear Radiation Drug Product
Table 109. GlaxoSmithKline Recent Developments/Updates
Table 110. Pfizer Corporation Information
Table 111. Pfizer Description and Business Overview
Table 112. Pfizer Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Pfizer Anti-Nuclear Radiation Drug Product
Table 114. Pfizer Recent Developments/Updates
Table 115. Onconova Corporation Information
Table 116. Onconova Description and Business Overview
Table 117. Onconova Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Onconova Anti-Nuclear Radiation Drug Product
Table 119. Onconova Recent Developments/Updates
Table 120. Novartis AG Corporation Information
Table 121. Novartis AG Description and Business Overview
Table 122. Novartis AG Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Novartis AG Anti-Nuclear Radiation Drug Product
Table 124. Novartis AG Recent Developments/Updates
Table 125. Teva Pharmaceuticals Corporation Information
Table 126. Teva Pharmaceuticals Description and Business Overview
Table 127. Teva Pharmaceuticals Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Teva Pharmaceuticals Anti-Nuclear Radiation Drug Product
Table 129. Teva Pharmaceuticals Recent Developments/Updates
Table 130. Clinigen Corporation Information
Table 131. Clinigen Description and Business Overview
Table 132. Clinigen Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Clinigen Anti-Nuclear Radiation Drug Product
Table 134. Clinigen Recent Developments/Updates
Table 135. Sun Pharmaceutical Corporation Information
Table 136. Sun Pharmaceutical Description and Business Overview
Table 137. Sun Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Sun Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 139. Sun Pharmaceutical Recent Developments/Updates
Table 140. Taj Pharmaceuticals Corporation Information
Table 141. Taj Pharmaceuticals Description and Business Overview
Table 142. Taj Pharmaceuticals Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Taj Pharmaceuticals Anti-Nuclear Radiation Drug Product
Table 144. Taj Pharmaceuticals Recent Developments/Updates
Table 145. Merro Pharmaceutical Corporation Information
Table 146. Merro Pharmaceutical Description and Business Overview
Table 147. Merro Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 148. Merro Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 149. Merro Pharmaceutical Recent Developments/Updates
Table 150. Luye Pharma Corporation Information
Table 151. Luye Pharma Description and Business Overview
Table 152. Luye Pharma Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 153. Luye Pharma Anti-Nuclear Radiation Drug Product
Table 154. Luye Pharma Recent Developments/Updates
Table 155. Mingren Pharma Corporation Information
Table 156. Mingren Pharma Description and Business Overview
Table 157. Mingren Pharma Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 158. Mingren Pharma Anti-Nuclear Radiation Drug Product
Table 159. Mingren Pharma Recent Developments/Updates
Table 160. Gilead Sciences Corporation Information
Table 161. Gilead Sciences Description and Business Overview
Table 162. Gilead Sciences Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 163. Gilead Sciences Anti-Nuclear Radiation Drug Product
Table 164. Gilead Sciences Recent Developments/Updates
Table 165. Johnson & Johnson Corporation Information
Table 166. Johnson & Johnson Description and Business Overview
Table 167. Johnson & Johnson Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 168. Johnson & Johnson Anti-Nuclear Radiation Drug Product
Table 169. Johnson & Johnson Recent Developments/Updates
Table 170. Merck KGaA Corporation Information
Table 171. Merck KGaA Description and Business Overview
Table 172. Merck KGaA Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 173. Merck KGaA Anti-Nuclear Radiation Drug Product
Table 174. Merck KGaA Recent Developments/Updates
Table 175. Genentech Inc. Corporation Information
Table 176. Genentech Inc. Description and Business Overview
Table 177. Genentech Inc. Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 178. Genentech Inc. Anti-Nuclear Radiation Drug Product
Table 179. Genentech Inc. Recent Developments/Updates
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Anti-Nuclear Radiation Drug Distributors List
Table 183. Anti-Nuclear Radiation Drug Customers List
Table 184. Anti-Nuclear Radiation Drug Market Trends
Table 185. Anti-Nuclear Radiation Drug Market Drivers
Table 186. Anti-Nuclear Radiation Drug Market Challenges
Table 187. Anti-Nuclear Radiation Drug Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-Nuclear Radiation Drug
Figure 2. Global Anti-Nuclear Radiation Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Anti-Nuclear Radiation Drug Market Share by Type in 2022 & 2029
Figure 4. Potassium Iodide (KI) Product Picture
Figure 5. Prussian Blue Product Picture
Figure 6. Diethylenetriamine Pentaacetate (DTPA) Product Picture
Figure 7. Filgrastim Product Picture
Figure 8. Amifostine Product Picture
Figure 9. Ex-Rad Product Picture
Figure 10. Global Anti-Nuclear Radiation Drug Market Value Comparison by Sales Channel (2024-2034) & (US$ Million)
Figure 11. Global Anti-Nuclear Radiation Drug Market Share by Sales Channel in 2022 & 2029
Figure 12. Online Sales
Figure 13. Offline Sales
Figure 14. Global Anti-Nuclear Radiation Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Anti-Nuclear Radiation Drug Market Size (2018-2029) & (US$ Million)
Figure 16. Global Anti-Nuclear Radiation Drug Sales (2018-2029) & (K Units)
Figure 17. Global Anti-Nuclear Radiation Drug Average Price (US$/Unit) & (2018-2029)
Figure 18. Anti-Nuclear Radiation Drug Report Years Considered
Figure 19. Anti-Nuclear Radiation Drug Sales Share by Manufacturers in 2022
Figure 20. Global Anti-Nuclear Radiation Drug Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Anti-Nuclear Radiation Drug Players: Market Share by Revenue in 2022
Figure 22. Anti-Nuclear Radiation Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Anti-Nuclear Radiation Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America Anti-Nuclear Radiation Drug Sales Market Share by Country (2018-2029)
Figure 25. North America Anti-Nuclear Radiation Drug Revenue Market Share by Country (2018-2029)
Figure 26. United States Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Anti-Nuclear Radiation Drug Sales Market Share by Country (2018-2029)
Figure 29. Europe Anti-Nuclear Radiation Drug Revenue Market Share by Country (2018-2029)
Figure 30. Germany Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific Anti-Nuclear Radiation Drug Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific Anti-Nuclear Radiation Drug Revenue Market Share by Region (2018-2029)
Figure 37. China Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Anti-Nuclear Radiation Drug Sales Market Share by Country (2018-2029)
Figure 45. Latin America Anti-Nuclear Radiation Drug Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Colombia Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Anti-Nuclear Radiation Drug Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Anti-Nuclear Radiation Drug Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Anti-Nuclear Radiation Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Anti-Nuclear Radiation Drug by Type (2018-2029)
Figure 56. Global Revenue Market Share of Anti-Nuclear Radiation Drug by Type (2018-2029)
Figure 57. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Anti-Nuclear Radiation Drug by Sales Channel (2018-2029)
Figure 59. Global Revenue Market Share of Anti-Nuclear Radiation Drug by Sales Channel (2018-2029)
Figure 60. Global Anti-Nuclear Radiation Drug Price (US$/Unit) by Sales Channel (2018-2029)
Figure 61. Anti-Nuclear Radiation Drug Value Chain
Figure 62. Anti-Nuclear Radiation Drug Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed